Summary
Amgen Inc.'s 2015 10-K report highlights a year of strong financial performance, characterized by an 8% increase in total revenues, reaching $21.7 billion, and a significant 35% rise in net income and diluted EPS. This growth was driven by a diverse product portfolio, with notable performance from Enbrel, Neulasta, Sensipar/Mimpara, XGEVA, and Prolia. The company continued its strategic focus on innovation, advancing its pipeline with six new product launches, including in oncology and cardiovascular disease, and making significant progress on key pipeline candidates like Parsabiv, Romosozumab, and Repatha. The report also emphasizes Amgen's commitment to transforming its operations for greater efficiency and reinvesting capital into R&D and shareholder returns through dividends and stock repurchases. However, the company faces increasing competition, particularly from biosimilars, and acknowledges the impact of patent expirations on key products like Neulasta and Epogen. Management expresses confidence in the company's long-term prospects, driven by ongoing R&D, new product launches, and strategic business development, while also acknowledging the persistent challenges of pricing pressures and regulatory environments.
Financial Highlights
55 data points| Revenue | $21.66B |
| Cost of Revenue | $4.23B |
| Gross Profit | $17.43B |
| SG&A Expenses | $4.85B |
| Operating Expenses | $13.19B |
| Operating Income | $8.47B |
| Interest Expense | $1.09B |
| Net Income | $6.94B |
| EPS (Basic) | $9.15 |
| EPS (Diluted) | $9.06 |
| Shares Outstanding (Basic) | 758.00M |
| Shares Outstanding (Diluted) | 766.00M |
Key Highlights
- 1Total revenues increased by 8% to $21.7 billion in 2015, with net income and diluted EPS growing by 35%, demonstrating strong financial performance.
- 2Amgen launched six innovative new products in 2015, including therapies for oncology and cardiovascular disease, and advanced several key pipeline candidates through regulatory submissions and positive clinical trial data.
- 3The company saw significant sales growth in key products like Prolia (+27%), XGEVA (+15%), and Sensipar/Mimpara (+22%), indicating successful market penetration and demand.
- 4Patent expirations for major products like Neulasta and Epogen in the US market were noted, along with the emergence of biosimilar competition, such as Zarxio for Neupogen.
- 5Operating expenses decreased by 5% to $13.2 billion, largely due to cost savings from transformation and process improvement initiatives, allowing for reinvestment in pipeline and launch products.
- 6Amgen returned significant capital to shareholders through dividends (increased by 30% year-over-year) and stock repurchases ($1.9 billion in 2015).
- 7The company continues to invest heavily in R&D, with $4.1 billion spent in 2015, focusing on oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience.